Vol 25, No 4 (2020)
Original research articles
Published online: 2020-07-01

open access

Page views 224
Article views/downloads 369
Get Citation

Connect on Social Media

Connect on Social Media

Pelvic radiation therapy with volumetric modulated arc therapy and intensity-modulated radiotherapy after renal transplant: A report of 3 cases

Pérez Álvarez Ileana1, Ramos Prudencio Rubi1, Lozano Ruiz Javier2, Macías González Sagrario3, Flores Balcazar Haydeé1
DOI: 10.1016/j.rpor.2020.04.003
Rep Pract Oncol Radiother 2020;25(4):548-555.

Abstract

Aim

Describe characteristics and outcomes of three patients treated with pelvic radiation therapy after kidney transplant.

Background

The incidence of pelvic cancers in kidney transplant (KT) recipients is rising. Currently it is the leading cause of death. Moreover, treatment is challenging because anatomical variants, comorbidities, and associated treatments, which raises the concern of using radiotherapy (RT). RT has been discouraged due to the increased risk of urethral/ureteral stricture and KT dysfunction.

Materials and methods

We reviewed the electronic health records and digital planning system of patients treated with pelvic RT between December 2013 and December 2018 to identify patients with previous KT.

Cases description

We describe three successful cases of KT patients in which modern techniques allowed full standard RT for pelvic malignances (2 prostate and 1 vaginal cancer) with or without elective pelvic nodal RT, without allograft toxicity at short and long follow-up (up to 60 months).

Conclusion

When needed, RT modern techniques remain a valid option with excellent oncologic results and acceptable toxicity. Physicians should give special considerations to accomplish all OAR dose constraints in the patient’s specific setting. Recent publications recommend KT mean dose <4 Gy, but graft proximity to CTV makes this unfeasible. We present 2 cases where dose constraint was not achieved, and to a short follow-up of 20 months renal toxicity has not been documented. We recommend the lowest possible mean dose to the KT, but never compromising the CTV coverage, since morbimortality from recurrent or progressive cancer disease outweighs the risk of graft injury.

Article available in PDF format

View PDF Download PDF file



Reports of Practical Oncology and Radiotherapy